Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2007

01-11-2007 | Review

Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis

Authors: Sofia Lionaki, J. Charles Jennette, Ronald J. Falk

Published in: Seminars in Immunopathology | Issue 4/2007

Login to get access

Abstract

Anti-neutrophil cytoplasmic autoantibodies (ANCA) and anti-glomerular basement membrane (GBM) necrotizing and crescentic glomerulonephritis are aggressive and destructive glomerular diseases that are associated with and probably caused by circulating ANCA and anti-GBM antibodies. These necrotizing lesions are manifested by acute nephritis and deteriorating kidney function often accompanied by distinctive clinical features of systemic disease. Prompt diagnosis requires clinical acumen that allows for the prompt institution of therapy aimed at removing circulating autoantibodies and quelling the inflammatory process. Continuing exploration of the etiology and pathogenesis of these aggressive inflammatory diseases have gradually uncovered new paradigms for the cause of and more specific therapy for these particular glomerular disorders and for autoimmune glomerular diseases in general.
Literature
1.
Jennette JC, Thomas DB (2007) Pauci-immune and antineutrophil cytoplasmic autoantibody-mediated crescentic glomerulonephritis and vasculitis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG (eds) Heptinstall’s pathology of the kidney. Lippincott, Williams & Wilkins, Philadelphia, pp 642–673
2.
Couser WG (1988) Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 11:449–464PubMed
3.
Jennette JC, Falk RJ (1998) Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 13(Suppl 1):16–20PubMed
4.
Jennette JC, Thomas DB (2001) Crescentic glomerulonephritis. Nephrol Dial Transplant 16(Suppl 6):80–82PubMed
5.
Davies DJ, Moran JE, Niall JF, Ryan GB (1982) Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 285:606CrossRef
6.
Van Der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, van der Giessen M, van der Hem GK, The TH (1985) Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1:425–429PubMed
7.
Falk RJ, Jennette JC (1988) Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318:1651–1657PubMedCrossRef
8.
Falk RJ (1990) ANCA-associated renal disease. Kidney Int 38:998–1010PubMed
9.
Jennette JC, Falk RJ (1997) Small-vessel vasculitis [see comments]. N Engl J Med 337:1512–1523PubMed
10.
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMed
11.
D’Agati V, Chander P, Nash M, Mancilla-Jimenez R (1986) Idiopathic microscopic polyarteritis nodosa: ultrastructural observations on the renal vascular and glomerular lesions. Am J Kidney Dis 7:95–110PubMed
12.
Ferrario F, Tadros MT, Napodano P, Sinico RA, Fellin G, D’Amico G (1994) Critical re-evaluation of 41 cases of “idiopathic” crescentic glomerulonephritis. Clin Nephrol 41:1–9PubMed
13.
Harris AA, Falk RJ, Jennette JC (1998) Crescentic glomerulonephritis with a paucity of glomerular immunoglobulin localization. Am J Kidney Dis 32:179–184PubMed
14.
Jennette JC (2003) Rapidly progressive crescentic glomerulonephritis. Kidney Int 63:1164–1177PubMed
15.
Jennette JC, Falk RJ (1995) Clinical and pathological classification of ANCA-associated vasculitis: what are the controversies? Clin Exp Immunol 101(Suppl 1):18–22PubMed
16.
Pettersson EE, Sundelin B, Heigl Z (1995) Incidence and outcome of pauci-immune necrotizing and crescentic glomerulonephritis in adults. Clin Nephrol 43:141–149PubMed
17.
Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143:621–631PubMed
18.
Savage CO, Harper L, Adu D (1997) Primary systemic vasculitis. Lancet 349:553–558PubMed
19.
Knight A, Ekbom A, Brandt L, Askling J (2006) Increasing incidence of Wegener’s granulomatosis in Sweden, 1975–2001. J Rheumatol 33:2060–2063PubMed
20.
Borgmann S, Haubitz M (2004) Genetic impact of pathogenesis and prognosis of ANCA-associated vasculitides. Clin Exp Rheumatol 22:S79–S86PubMed
21.
Jagiello P, Aries P, Arning L, Wagenleiter SE, Csernok E, Hellmich B, Gross WL, Epplen JT (2005) The PTPN22 620 W allele is a risk factor for Wegener’s granulomatosis. Arthritis Rheum 52:4039–4043PubMed
22.
Gregersen PK, Lee HS, Batliwalla F, Begovich AB (2006) PTPN22: Setting thresholds for autoimmunity. Semin Immunol 18:214–223PubMed
23.
Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Jennette JC, Nachman PH (2007) Association of thyroid disease and its treatment with ANCA small vessel vasculitis. Nephrol Dial Transplant (in press, Aug 8). DOI 10.​1093/​ndt/​gfm493
24.
Hogan SL, Satterly KK, Dooley MA, Nachman PH, Jennette JC, Falk RJ (2001) Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol 12:134–142PubMed
25.
Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG (2003) Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum 48:814–823PubMed
26.
Hogan SL, Cooper GC, Savitz DA, Nylander-French LA, Parks CG, Chin H, Jennette CE, Lionaki S, Jennette JC, Falk RJ (2007) Association of silica exposure with ANCA-associated glomerulonephritis: a population-based case-control study in the Southeastern United States. Clin J Am Soc Nephrol 2:290–299PubMed
27.
ten Holder SM, Joy MS, Falk RJ (2002) Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 36:130–147PubMed
28.
29.
Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, De Jong PE, Kallenberg CG (1994) Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis [see comments]. Ann Intern Med 120:12–17PubMed
30.
Kallenberg CG, Stegeman CA, Tervaert JW (1996) Staphylococcus aureus, trimethoprim-sulfamethoxazole, and Wegener’s granulomatosis. Sarcoidosis Vasc Diffuse Lung Dis 13:253–255PubMed
31.
Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, Jayne DR, Rasmussen N, Bruijn JA, Hagen EC (2002) Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 61:80–89PubMed
32.
Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW (1994) Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 46:1–15PubMed
33.
Savige J, Davies D, Falk RJ, Jennette JC, Wiik A (2000) Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int 57:846–862PubMed
34.
Bansal PJ, Tobin MC (2004) Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 93:398–401PubMedCrossRef
35.
Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ (2005) Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 45:758–761PubMed
36.
Slot MC, Tervaert JW, Boomsma MM, Stegeman CA (2004) Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 51:269–273PubMed
37.
Kyndt X, Reumaux D, Bridoux F, Tribout B, Bataille P, Hachulla E, Hatron PY, Duthilleul P, Vanhille P (1999) Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 106:527–533PubMed
38.
Falk RJ, Terrell RS, Charles LA, Jennette JC (1990) Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87:4115–4119PubMed
39.
Schreiber A, Busjahn A, Luft FC, Kettritz R (2003) Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol 14:68–75PubMed
40.
Schreiber A, Luft FC, Kettritz R (2004) Membrane proteinase 3 expression and ANCA-induced neutrophil activation. Kidney Int 65:2172–2183PubMed
41.
Charles LA, Caldas ML, Falk RJ, Terrell RS, Jennette JC (1991) Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 50:539–546PubMed
42.
Kettritz R, Jennette JC, Falk RJ (1997) Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol 8:386–394PubMed
43.
Radford DJ, Luu NT, Hewins P, Nash GB, Savage CO (2001) Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum 44:2851–2861PubMed
44.
Moon KC, Park SY, Kim HW, Hong HK, Lee HS (2002) Expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in human crescentic glomerulonephritis. Histopathology 41:158–165PubMed
45.
Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110:955–963PubMed
46.
Xiao H, Heeringa P, Liu Z, Huugen D, Hu P, Maeda N, Falk RJ, Jennette JC (2005) The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 167:39–45PubMed
47.
Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P (2005) Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 167:47–58PubMed
48.
Jennette JC, Xiao H, Falk RJ (2006) Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 17:1235–1242PubMed
49.
Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC (2007) Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170:52–64PubMed
50.
Little MA, Smyth CL, Yadav R, Ambrose L, Cook HT, Nourshargh S, Pusey CD (2005) Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106:2050–2058PubMed
51.
Pendergraft WF, Preston GA, Shah RR, Tropsha A, Carter CW, Jennette JC, Falk RJ (2004) Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 10:72–79PubMed
52.
Falk RJ, Hogan S, Carey TS, Jennette JC (1990) Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 113:656–663PubMed
53.
Woodworth TG, Abuelo JG, Austin HA III, Esparza A (1987) Severe glomerulonephritis with late emergence of classic Wegener’s granulomatosis. Report of 4 cases and review of the literature. Medicine (Baltimore) 66:181–191
54.
Guillevin L, Lhote F (1997) Classification and management of necrotising vasculitides. Drugs 53:805–816PubMed
55.
Lhote F, Guillevin L (1995) Polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin North Am 21:911–947PubMed
56.
Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76–85PubMed
57.
Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis: an analysis of 158 patients [see comments]. Ann Intern Med 116:488–498PubMed
58.
Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr (1990) The American college of rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107PubMedCrossRef
59.
Nachman PH, Reisner HM, Yang JJ, Jennette JC, Falk RJ (1996) Shared idiotypy among patients with myeloperoxidase-anti-neutrophil cytoplasmic autoantibody associated glomerulonephritis and vasculitis. Lab Invest 74:519–527PubMed
60.
Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM (1985) Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 56:467–483PubMed
61.
Daha MR, Falk RJ (1990) Anti-myeloperoxidase antibodies and clinical associations. Neth J Med 36:152–153PubMed
62.
Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ (1996) Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:23–32PubMed
63.
Jennette JC, Wilkman AS, Falk RJ (1989) Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 135:921–930PubMed
64.
Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC Jr, Hoffman GS, McCune WJ, St Clair EW, Specks U, Spiera R, Petri M, Stone JH, Wegener’s Granulomatosis Etanercept Trial Research Group (2005) Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142:620–626PubMed
65.
Weidner S, Hafezi-Rachti S, Rupprecht HD (2006) Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 55:146–149PubMed
66.
Bautz DJ, Lionaki S, Yang JJ, Hogan SL, Hamra J, Parker CE, Jennette JC (2006) The search for complementary PR3 proteins identified plasminogen as an autoantigen in PR3-ANCA disease. J Am Soc Nephrol 85A [Abstract SA-FC069]
67.
Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, Blockmans D, Cordier JF, Delaval P, Puechal X, Lauque D, Viallard JF, Zoulim A, Guillevin L (2005) Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann Intern Med 143:632–638PubMed
68.
Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, Grasselli C, Pavone L, Gregorini G, Monti S, Frassi M, Vecchio F, Corace C, Venegoni E, Buzio C (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome. Arthritis Rheum 52:2926–2935PubMed
69.
Nachman PH, Hogan SL, Jennette JC, Falk RJ (1996) Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:33–39PubMed
70.
Novack SN, Pearson CM (1971) Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med 284:938–942PubMedCrossRef
71.
de Groot K, Jayne DR, Tesar V, Savage CO (2005) European, multicenter randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis for the European Vasculitis Study Group. J Am Soc Nephrol 7A
72.
Stegeman CA, Tervaert JW, De Jong PE, Kallenberg CG (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16–20PubMed
73.
Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ (2003) Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42:1149–1153PubMed
74.
Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM (1991) Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 40:757–763PubMed
75.
Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, Clark W, Morrin P, Posen G, Bernstein K (1992) A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 20:261–269PubMed
76.
de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noel LH, Ferrario F, Waldherr R, Hagen EC, Bruijn JA, Bajema IM (2006) Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 17:2264–2274PubMed
77.
Beimler JH, Andrassy K (2004) Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much? Pediatr Nephrol 19:949–955PubMed
78.
Jayne D, Rasmussen N, Andrassy K, Bacon P, Cohen Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36–44PubMed
79.
Langford CA, Talar-Williams C, Barron KS, Sneller MC (1999) A staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42:2666–2673PubMed
80.
Langford CA, Talar W, Sneller MC (2000) Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 43:1836–1840PubMed
81.
Furst DE (1995) Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 34(Suppl 2):20–25PubMed
82.
Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH (2005) A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 20(12):2725–2732PubMed
83.
Koukoulaki M, Jayne DR (2006) Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 102(3–4):c100–c107PubMed
84.
Cooper JD, Hogan SL, Chin H, Falk RJ, Nachman PH (2006) Mycophenolate mofetil plus cyclosporine therapy for active ANCA vasculitis. J Am Soc Nephrol 547A [Abstract F-PO1128]
85.
Flossmann O, Jones RB, Jayne DR, Luqmani RA (2006) Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis 65:841–844PubMed
86.
Edwards JC, Cambridge G (2005) Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 44:151–156
87.
Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, Heller M, Gross WL (2000) An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43:1021–1032PubMed
88.
Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, Van Der Woude FJ, de Lind van Wijngaarden RA, Pusey CD (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180–2188PubMed
89.
Allen A, Pusey C, Gaskin G (1998) Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 9:1258–1263PubMed
90.
Weidanz F, Day CJ, Hewins P, Savage CO, Harper L (2007) Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis 50:36–46PubMed
91.
Haubitz M, Koch KM, Brunkhorst R (1998) Survival and vasculitis activity in patients with end-stage renal disease due to Wegener’s granulomatosis. Nephrol Dial Transplant 13:1713–1718PubMed
92.
Nachman PH, Segelmark M, Westman K, Hogan SL, Satterly KK, Jennette JC, Falk R (1999) Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int 56:1544–1550PubMed
93.
Gera M, Griffin MD, Specks U, Leung N, Stegall MD, Fervenza FC (2007) Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosuppression. Kidney Int 71:1296–1301PubMed
94.
Goodpasture EW (1919) The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci 158:863–870
95.
Stanton MC, Tange JD (1958) Goodpasture’s syndrome (pulmonary haemorrhage associated with glomerulonephritis). Australas Ann Med 7:132–144PubMed
96.
Jennette JC, Nickeleit V (2007) Anti-glomerular basement membrane glomerulonephritis and Goodpasture’s syndrome. In: Jennette JC, Olson JL, Schwartz MM, Silva FG (eds) Heptinstall’s pathology of the kidney, vol 1. Lippincott Williams & Wilkins, Philadelphia, pp 613–642
97.
Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JW (2005) Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 46:253–262PubMed
98.
Bolton WK (1996) Goodpasture’s syndrome. Kidney Int 50:1753–1766PubMed
99.
Borza DB, Chedid MF, Colon S, Lager DJ, Leung N, Fervenza FC (2005) Recurrent Goodpasture’s disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am J Kidney Dis 45:397–406PubMed
100.
Kalluri R, Wilson CB, Weber M, Gunwar S, Chonko AM, Neilson EG, Hudson BG (1995) Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. J Am Soc Nephrol 6:1178–1185PubMed
101.
Butkowski RJ, Wieslander J, Kleppel M, Michael AF, Fish AJ (1989) Basement membrane collagen in the kidney: regional localization of novel chains related to collagen IV. Kidney Int 35:1195–1202PubMed
102.
Daly C, Conlon PJ, Medwar W, Walshe JJ (1996) Characteristics and outcome of anti-glomerular basement membrane disease: a single-center experience. Ren Fail 18:105–112PubMed
103.
Savage CO, Pusey CD, Bowman C, Rees AJ, Lockwood CM (1986) Antiglomerular basement membrane antibody mediated disease in the British Isles 1980–4. Br Med J (Clin Res Ed) 292:301–304
104.
Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, Lesavre P, Ludemann J, Rasmussen N, Sinico RA, Wiik A, Van Der Woude FJ (1998) Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 53:743–753PubMed
105.
Levy JB, Turner AN, Rees AJ, Pusey CD (2001) Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134:1033–1042PubMed
106.
Dahlberg PJ, Kurtz SB, Donadio JV, Holley KE, Velosa JA, Williams DE, Wilson CB (1978) Recurrent Goodpasture’s syndrome. Mayo Clin Proc 53:533–537PubMed
107.
Segelmark M, Hellmark T, Wieslander J (2003) The prognostic significance in Goodpasture’s disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract 94:c59–c68PubMed
108.
Hind CR, Paraskevakou H, Lockwood CM, Evans DJ, Peters DK, Rees AJ (1983) Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet 1:263–265PubMed
109.
Herody M, Bobrie G, Gouarin C, Grunfeld JP, Noel LH (1993) Anti-GBM disease: predictive value of clinical, histological and serological data. Clin Nephrol 40:249–255PubMed
110.
Kaplan AA (2003) The use of apheresis in immune renal disorders. Ther Apher Dial 7:165–172PubMed
111.
Flores JC, Taube D, Savage CO, Cameron JS, Lockwood CM, Williams DG, Ogg CS (1986) Clinical and immunological evolution of oligoanuric anti-GBM nephritis treated by haemodialysis. Lancet 1:5–8PubMed
112.
Khandelwal M, McCormick BB, Lajoie G, Sweet J, Cole E, Cattran DC (2004) Recurrence of anti-GBM disease 8 years after renal transplantation. Nephrol Dial Transplant 19:491–494PubMed
113.
Hellmark T, Segelmark M, Wieslander J (1997) Anti-GBM antibodies in Goodpasture syndrome; anatomy of an epitope. Nephrol Dial Transplant 12:646–648PubMed
114.
Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD (2004) Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 66:1535–1540PubMed
115.
Huang D, Zhou Y, Hoffman GS (2001) Pathogenesis: immunogenetic factors. Best Pract Res Clin Rheumatol 15:239–258PubMed
116.
Giscombe R, Wang X, Huang D, Lefvert AK (2002) Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener’s granulomatosis. J Rheumatol 29:950–953PubMed
117.
Zhou Y, Huang D, Paris PL, Sauter CS, Prock KA, Hoffman GS (2004) An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener’s granulomatosis. Arthritis Rheum 50:2645–2650PubMed
118.
Gencik M, Meller S, Borgmann S, Sitter T, Menezes Saecker AM, Fricke H, Epplen JT (2000) The association of CD18 alleles with anti-myeloperoxidase subtypes of ANCA-associated systemic vasculitides. Clin Immunol 94:9–12PubMed
119.
Meller S, Jagiello P, Borgmann S, Fricke H, Epplen JT, Gencik M (2001) Novel SNPs in the CD18 gene validate the association with MPO-ANCA+ vasculitis. Genes Immun 2:269–272PubMed
120.
Jagiello P, Gencik M, Arning L, Wieczorek S, Kunstmann E, Csernok E, Gross WL, Epplen JT (2004) New genomic region for Wegener’s granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet 114:468–477PubMed
121.
Zhou Y, Huang D, Farver C, Hoffman GS (2003) Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener’s granulomatosis. J Rheumatol 30:1541–1547PubMed
122.
Borgmann S, Endisch G, Hacker UT, Song BS, Fricke H (2003) Proinflammatory genotype of interleukin-1 and interleukin-1 receptor antagonist is associated with ESRD in proteinase 3-ANCA vasculitis patients. Am J Kidney Dis 41:933–942PubMed
123.
Bartfai Z, Gaede KI, Russell KA, Murakozy G, Muller-Quernheim J, Specks U (2003) Different gender-associated genotype risks of Wegener’s granulomatosis and microscopic polyangiitis. Clin Immunol 109:330–337PubMed
124.
Zhou Y, Giscombe R, Huang D, Lefvert AK (2002) Novel genetic association of Wegener’s granulomatosis with the interleukin 10 gene. J Rheumatol 29:317–320PubMed
125.
Gencik M, Meller S, Borgmann S, Fricke H (2000) Proteinase 3 gene polymorphisms and Wegener’s granulomatosis. Kidney Int 58:2473–2477PubMed
126.
von Vietinghoff S, Busjahn A, Schonemann C, Massenkeil G, Otto B, Luft FC, Kettritz R (2006) Major histocompatibility complex HLA region largely explains the genetic variance exercised on neutrophil membrane proteinase 3 expression. J Am Soc Nephrol 17:3185–3191
127.
Tsuchiya N, Kobayashi S, Kawasaki A, Kyogoku C, Arimura Y, Yoshida M, Tokunaga K, Hashimoto H (2003) Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: association of HLA-DRB1*0901 with microscopic polyangiitis. J Rheumatol 30:1534–1540PubMed
128.
Szyld P, Jagiello P, Csernok E, Gross WL, Epplen JT (2006) On the Wegener granulomatosis associated region on chromosome 6p21.3. BMC Med Genet 7:21PubMed
129.
Griffith ME, Lovegrove JU, Gaskin G, Whitehouse DB, Pusey CD (1996) C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 11:438–443PubMed
130.
Segelmark M, Elzouki AN, Wieslander J, Eriksson S (1995) The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3- ANCA-positive vasculitis. Kidney Int 48:844–850PubMed
131.
Elzouki AN, Segelmark M, Wieslander J, Eriksson S (1994) Strong link between the alpha 1-antitrypsin PiZ allele and Wegener’s granulomatosis. J Intern Med 236:543–548PubMedCrossRef
132.
Dijstelbloem HM, Scheepers RH, Oost WW, Stegeman CA, van der Pol WL, Sluiter WJ, Kallenberg CG, van de Winkel JG, Tervaert JW (1999) Fcgamma receptor polymorphisms in Wegener’s granulomatosis: risk factors for disease relapse. Arthritis Rheum 42:1823–1827PubMed
133.
Edberg JC, Wainstein E, Wu J, Csernok E, Sneller MC, Hoffman GS, Keystone EC, Gross WL, Kimberly RP (1997) Analysis of FcgammaRII gene polymorphisms in Wegener’s granulomatosis. Exp Clin Immunogenet 14:183–195PubMed
134.
Tse WY, Abadeh S, Jefferis R, Savage CO, Adu D (2000) Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin Exp Immunol 119:574–577PubMed
135.
Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh L, Heward JM, Gough SC, de Smith A, Blakemore AI, Froguel P, Owen CJ, Pearce SH, Teixeira L, Guillevin L, Graham DS, Pusey CD, Cook HT, Vyse TJ, Aitman TJ (2007) FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 39:721–723PubMed
Metadata
Title
Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis
Authors
Sofia Lionaki
J. Charles Jennette
Ronald J. Falk
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 4/2007
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-007-0093-0

Other articles of this Issue 4/2007

Seminars in Immunopathology 4/2007 Go to the issue

Review

Leukocytes in glomerular injury

Review

Complement in glomerular injury

Review

Minimal change nephropathy and focal segmental glomerulosclerosis

Review

Immunopathogenesis of IgAN

Review

Modulation of glomerulosclerosis

Review

B cells in glomerulonephritis: focus on lupus nephritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits